Tags: Drug.
Secukinumab is a human monoclonal antibody designed for the treatments of uveitis rheumatoid arthritis and psoriasis. It targets member A from the cytokine family of interleukin 17.Secukinumab was developed by Novartis Pharma AG and has completed Phase II clinical trials for plaque psoriasis in 2011.It is also in a phase II clinical trial for Multiple Sclerosis as it has exhibited efficacy in treating experimental autoimmune encephalomyelitis (EAE) an animal model of MS.